Immunome develops targeted cancer therapies, with a focus on antibody drug conjugates and an investigational treatment for desmoid tumors. IMNM reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 1 | Stifel | Initiated | Hold | |
| Sep 21 | Alliance Global Partners | Initiated | Buy | |
| Aug 12 | Truist Securities | Target raised | Buy | |
| Aug 12 | Wedbush | Target raised | Buy | |
| Jun 12 | Wedbush | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in IMNM in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMNM is in one of them and how their past IMNM trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IMNM in an article yet. Here's the latest on the wider market.
About Immunome
Immunome is a biotechnology company based in Bothell, Washington, that develops targeted cancer treatments. Its main focus is antibody drug conjugates, a type of therapy that carries cancer fighting drugs to tumor cells, along with other oncology therapies. Its lead candidate, varegacestat, is an investigational oral treatment for desmoid tumors, a rare connective tissue tumor. The company aims to serve cancer patients and the doctors who treat them.
- Headquarters
- Bothell, WA